Projects per year
Personal profile
Personal profile
Dr. Pingali is board certified by the American Board of Internal Medicine in medical oncology and hematology. His primary focus is on hematologic malignancies and stem cell transplantation. After completing his medical training in India, Dr. Pingali received training in various reputable programs in the United Kingdom as part of senior house officer training after which he moved to the United States. He completed his residency in internal medicine at Gundersen Lutheran Medical Center in Wisconsin. He then completed a fellowship in hematology and oncology at the Medical College of Wisconsin, and a fellowship in stem cell transplantation at the University of Texas MD Anderson Cancer Center.
Dr. Pingali is a member of the American Society of Clinical Oncology, American Society of Hematology and the American Society for Blood and Marrow Transplantation. He sees patients at Houston Methodist Hospital.
Research Area Keywords
- Cancer
- Clinical Translation & Trials
- Molecular Medicine
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) an dCD30-expressing Peripheral T-cell Lymphoma (PTCL) in Older Patients or Patients With Significant Comorbidities Ineligible for Standard Chemotherapy
Pingali, S. R., Darcourt, J., Petkova, J. & Rice, L.
7/8/20 → …
Project: Clinical Trial
A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Pingali, S. R., Abdelrahim, M., Bernicker, E. H., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Petkova, J., Randhawa, J., Rice, L. & Singh, M.
7/8/20 → …
Project: Clinical Trial
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Pingali, S. R., Abdelrahim, M., Chang, J. C., Darcourt, J., Heyne, K., Niravath, P. A., Randhawa, J. & Zhang, J.
8/9/19 → …
Project: Clinical Trial
CardOnc screening
Trachtenberg, B. H., Bhimaraj, A., Guha, A., Niravath, P. A., Patel, T. & Pingali, S. R.
2/1/17 → …
Project: Clinical Trial
Research Output
Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors
Anand, K., Sahu, G., Burns, E., Ensor, A., Ensor, J., Pingali, S. R., Subbiah, V. & Iyer, S. P., Aug 18 2020, In : ESMO Open. 5, 4, e000866.Research output: Contribution to journal › Article
Open Access
Mycobacterial Infections With Ruxolitinib: A Retrospective Pharmacovigilance Review
Anand, K., Burns, E. A., Ensor, J., Rice, L. & Pingali, S. R., Jan 2020, In : Clinical Lymphoma, Myeloma and Leukemia. 20, 1, p. 18-23 6 p.Research output: Contribution to journal › Article
2
Scopus
citations
Radiation therapy in primary mediastinal large B-cell lymphoma treated with DA-R-EPOCH
Gentille, C., Anand, K., Dalwadi, S., Puri, A., Farach, A. & Pingali, S. R., Jul 1 2020, In : Clinical Case Reports. 8, 7, p. 1153-1155 3 p.Research output: Contribution to journal › Article
T-cell lymphoma secondary to checkpoint inhibitor therapy
Anand, K., Ensor, Jr., J. E., Pingali, S. R., Hwu, P., Duvic, M., Chiang, S., Miranda, R., Zu, Y. & Iyer, S., Feb 28 2020, In : Journal for immunotherapy of cancer. 8, 1, e000104.Research output: Contribution to journal › Article
Acute myeloid leukemia with eosinophilia after cyclin-dependent kinases 4/6 inhibitor treatment due to underlying clonal hematopoiesis of indeterminate potential
Anand, K., Kumar, P., Pingali, S. R., Pati, D. & Iyer, S. P., Mar 1 2019, In : American Journal of Hematology. 94, 3, p. E82-E85Research output: Contribution to journal › Letter